Charles River and Deciphex Expand Partnership to Enhance Digital Pathology with Exclusive Image Management Solutions Charles River Laboratories (NYSE: CRL) and Deciphex, a leader in AI-powered digital pathology, have announced the next phase of their strategic collaboration. The focus will…
Ellipses Licenses First-in-Class Novel Immuno-Oncology Agent Ellipses Pharma Limited (“Ellipses”), a global drug development company dedicated to advancing cancer treatments, announced today that it has in-licensed the global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody targeting CNTN4, a recently…
RenovoRx Closes $12.1 Million Public Offering of Common Stock RenovoRx, Inc. (Nasdaq: RNXT), a life sciences company focused on developing targeted oncology therapies, has successfully closed its previously announced $12.1 million underwritten public offering of common stock. The offering, which…
Particle Health Earns Certification for Surescripts Medication History for Populations Particle Health, a leading intelligent data platform that aggregates and delivers actionable patient insights to healthcare organizations, has announced the successful completion of its certification for Surescripts Medication History for…
Glox Therapeutics Appoints Dr. Michael Murray as Chair and Dr. Nel Moore to Scientific Advisory Board Glox Therapeutics, a leader in developing precision antibiotic therapies using naturally occurring bacteriocins, has announced the appointment of Dr. Michael Murray as Chair of…
Owens & Minor Launches ByramConnect Digital Platform for Chronic Health Conditions Byram Healthcare, a leader in home-based care and a part of Owens & Minor (NYSE: OMI), has recently introduced ByramConnect™, a personalized digital health program powered by the Welldoc…
Silobreaker Partners with Health-ISAC to Offer Free Trial of Threat Intelligence Platform Silobreaker, a leading security and threat intelligence technology company, has announced a new partnership with the Health Information Sharing and Analysis Center (Health-ISAC) as a Community Services Partner.…
Blackstone Life Sciences and Anthos Therapeutics Reach Deal for Novartis to Acquire Anthos for up to $3.1 Billion Blackstone Life Sciences and Anthos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on transformative therapies for cardiometabolic diseases, have announced a significant…
LIB Therapeutics Announces FDA Acceptance of Lerodalcibep BLA for LDL-C Reduction LIB Therapeutics Inc., a late-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for Lerodalcibep. This…
Arrowhead Pharmaceuticals Closes Global License and Collaboration with Sarepta Therapeutics Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the successful closing of its global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). The agreement, initially announced on November 26, 2024,…
Pan-Am Dental Completes Two Acquisitions, Joins Top 10 U.S. Dental Lab Groups Caymus Equity Partners (“Caymus Equity”) is excited to announce the successful acquisitions of JB Dental Lab (“JB”) and Avaneer Dental Studio (“Avaneer”) by its portfolio company, Pan-Am Dental…
Fresenius Kabi Launches Synthetic Calcitonin Salmon Injection, USP Fresenius Kabi, a subsidiary of Fresenius, announced the launch of Calcitonin Salmon Injection, USP Synthetic, a calcium-regulating medication designed to treat symptomatic Paget’s disease of the bone and hypercalcemia. This injection is…